While tremendous progress has been made over the last 20 years improving the 5 year survival of myeloma patients from 30 to >50%, it remains an incurable disease, characterised by increasing burdens of infection, bone disease, renal insufficiency and bone marrow failure due to both the underling disease and cumulative treatment toxicities. The discovery of myeloma specific antigens, such as BCMA, have allowed the development of new therapies that harness the power of the immune system to kill myeloma cells without the cost of a high treatment related mortality and graft versus host disease that hampered the application of allogeneic stem cell transplantation in Myeloma. I will explore the pre-clinical and trial data related to chimeric antigen receptor T cells (Car T) and bispecific T cell engaging antibodies; two competing strategies to target myeloma with T cells that have shown promising results and are likely to be approved in the next year for the treatment of myeloma.